Dexamethasone Therapy in VLBW Infants at Risk of CLD
NCT00011362
Completed
Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.
Gender:
ALL
Ages:
Between 13 days and 15 days
Trial Updated:
03/20/2019
Locations: Stanford University, Palo Alto, California +12 locations
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Register for Updates
Diagnosing Natriuretic Peptide Deficiency
NCT03035929
Completed
In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies. Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single d... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/20/2019
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Healthy, Lean
Register for Updates
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
NCT01383928
Completed
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO) ixazomib administered twice-weekly in combination with lenalidomide and low-dose dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2019
Locations: UCSF Medical Center, Berkeley, California +19 locations
Conditions: Multiple Myeloma
Register for Updates
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
NCT00807599
Completed
The purpose of this study is to compare the effects, good and bad, of two ways to treat patients with standard-risk symptomatic multiple myeloma. Patients with standard-risk myeloma have myeloma with specific features: levels of 2 blood tests have to be in a specific range and there can be no myeloma tumors found outside of the bones or bone marrow, the areas where myeloma is usually discovered. In past clinical studies, patients with standard-risk myeloma have done well with intensive therapy i... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/14/2019
Locations: Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey +6 locations
Conditions: Multiple Myeloma
Register for Updates
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT02518750
Terminated
This is a phase-II study to evaluate the efficacy of a salvage regimen in children with relapsed T-cell ALL or lymphoma. Peg-asparaginase, mitoxantrone, intrathecal triples (IT) (intrathecal methotrexate/hydrocortisone/cytarabine) (ITMHA) and dexamethasone are commonly used drugs to treat relapsed or refractory acute lymphocytic leukemia or lymphoma (ALL). In this study, the investigators want to know if adding three drugs called panobinostat, bortezomib and liposomal vincristine (VSLI) to this... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/08/2019
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
Register for Updates
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis
NCT02625181
Completed
The purpose of this study is to determine how automated recommendations are best presented to optimize the adherence to guidelines on prophylaxis for nausea and vomiting after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2019
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Postoperative Nausea and Vomiting
Register for Updates
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
NCT01440582
Completed
The goal of this clinical research study is to find the highest tolerable dose of the drug panobinostat that can be given in combination with the drugs Velcade (bortezomib), Revlimid (lenalidomide), and Decadron (dexamethasone) to patients with MM. The safety of this drug combination will also be studied. Panobinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myeloma
Register for Updates
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
NCT02725008
Completed
Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.
Gender:
ALL
Ages:
Between 18 months and 20 years
Trial Updated:
02/25/2019
Locations: New York Methodist Hospital, Brooklyn, New York
Conditions: Asthma
Register for Updates
Long Term Effectiveness of Trigger Finger Injections With Triamcinolone vs. Dexamethasone
NCT03641508
Completed
Trigger finger (stenosing tenosynovitis) is a very common condition and in office treatment with corticosteroid injection is widely accepted to be first line treatment. Previous studies have reported resolution of triggering after injection at rates ranging from 50% to 93%. Many factors contribute to this variability, including duration of symptoms, presence of diabetes, etc. This study will be a single center, prospective, randomized control trial. Patients will be collected into two different... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/14/2019
Locations: University of Iowa, Iowa City, Iowa
Conditions: Trigger Finger Disorder
Register for Updates
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00968253
Completed
The goal of Phase I of this clinical research study is to find the highest tolerable dose of RAD001 (everolimus) when given in combination with the standard chemotherapy regimens to patients with ALL. The goal of Phase II of this study is to learn if the drug combinations can help to control ALL. The safety of these drug combinations will be also studied in both phases.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
02/05/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Acute Lymphocytic Leukemia
Register for Updates
Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema
NCT02471651
Completed
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema. However, some patients continue to experience persistent diabetic macular edema and poor vision despite continued laser and/or anti-vegf therapy. Recent clinical trials suggest that due to inflammatory mediators dexamethasone intravitreal implant (0.7mg) may be a good alternative therapy for individuals unresponsive to laser photocoagulat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2019
Locations: California Retina Consultants, Bakersfield, California +3 locations
Conditions: Diabetic Macular Edema
Register for Updates
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
NCT03168100
Withdrawn
The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients. However, some patients still relapse early during maintenance treatment meaning that better options are still needed. This study will evaluate a treatment regimen that alternates two different 3-drug regimens every eight weeks for patients that have previously completed autologous stem cell transplant. The two regimens are bortezomib, le... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/25/2019
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates